Navigation Links
PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
Date:10/16/2008

tial new drug application submissions," said Gadi Saarony, Corporate Vice President and Worldwide Head, PAREXEL Consulting. "More than ever, biopharmaceutical companies should focus on reaping the greatest return on their R&D investments, maximizing product value at every stage of the lifecycle, and gaining the most efficiency from the development process. Crucial decisions must be made early in development planning, including which regulatory approaches to apply to achieve first-cycle approval."

"With continuing focus on first-cycle approvals for new drugs, especially under FDA Good Review Management Practices, our goal was to provide biopharmaceutical companies with a real-world metric on the value of first-cycle approvals," said Mark Mathieu, Director of Strategic Research at PAREXEL Consulting. "Our data show that priority designations are now closely linked to first-cycle approvals for both NMEs and NDAs. As a result, this metric can help biopharmaceutical companies assess the value of the new priority review vouchers available under the FDA Amendments Act."

The Getting to Approval white paper is part of PAREXEL Consulting's Intelligent Development Series, which provides data and insights in support of successful biopharmaceutical and medical device product development. The white paper is available at http://www.PAREXELConsulting.com/firstcycleapproval.

About PAREXEL Consulting

PAREXEL Consulting is a leading life sciences consultancy that helps companies design and execute their biopharmaceutical and medical device product strategies through our unique fusion of scientific, regulatory, and business expertise. Our approach helps clients manage risk, and drives superior quality and performance for clients worldwide. The firm has more than 270 experts, and serves clients on a global basis. For further information visit:

SOURCE PAREXEL International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
2. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
3. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
4. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
5. PAREXEL Closes the Acquisition of ClinPhone
6. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
7. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
8. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
10. PAREXEL Expands Global Clinical Logistics Capabilities
11. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and ... addition of Jain PharmaBiotech,s new report ... to their offering. The scope ... in situ hybridization (FISH), comparative genomic hybridization ... application of nanobiotechnology, microarrays, real-time polymerase chain ...
(Date:9/2/2015)... Aytu BioScience, Inc. (OTCQB: AYTU), a specialty ... related conditions, announced today that it has closed the ... financing, raising a total of $5.175 million, which includes ... Josh Disbrow , Chief Executive Officer ... intended to be used to conduct clinical studies for ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical ... From vital sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ... real-time clinical decisions with simultaneous access to high precision medical images and electronic ...
(Date:9/1/2015)... Swecure, ein Biotechnologieunternehmen, ... Entwicklung neuartiger Therapien für Störungen des Immunsystems ... konzentriert, erhält vom US Patent and Trademark ... patentiert wird. Das Medikament basiert auf einem ... und Entzündungen vorbeugt.   Das Medikament, ...
Breaking Biology Technology:Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... SAN DIEGO, Jan. 19, 2011 LifeVantage Corporation ... science-based solutions to oxidative stress, announced preliminary unaudited net revenue ... net revenue of approximately $7.4 million for the three month ... approximately $1.0 million or 15% over net revenue of $6.4 ...
... Inc. (OTC Bulletin Board: RGIN ) a ... regenerative cell therapies to restore the health of damaged ... feedback from attendees following their presentations at the OneMedForum ... conference was CEO Randall McCoy and senior Board Members ...
... This release is available in German . ... Ralph G. Nuzzo paved the way for use of the ... without that innovation. Professor Nuzzo is now honored with the ... includes guest visits to the Institute of Functional Interfaces (IFG) ...
Cached Biology Technology:LifeVantage Announces Preliminary Unaudited Second Quarter 2011 Results 2LifeVantage Announces Preliminary Unaudited Second Quarter 2011 Results 3Regenicin Receives Positive Feedback at OneMedForum Conference 2New impulses for surface research 2
(Date:8/19/2015)... Aug. 19, 2015  VOXX International Corporation (Nasdaq: ... entered into a Definitive Agreement to purchase the ... authentication market leader EyeLock through an acquiring entity.  ... a controlling interest in the acquiring entity. The ... of due diligence.  Expanding on its existing supply ...
(Date:8/12/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is proud to announce that iMedNet ... platform, has led the way to significant and unprecedented ...   Q2 2015 and Q1 2015 were, respectively, the ... sold in the company,s 15 year history.  In addition, ...
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... Ph.D., member of the Basic Sciences Division at Fred ... in the American Academy of Arts & Sciences, or ... honorary societies and independent policy-research centers.She is among 190 ... the AAAS 2008 class of fellows. Drawn from the ...
... The key focus of the Diogenes study is to identify ... after initial successful weight loss. To participate in the ... least 8% of their body weight, before the whole family ... and randomised to one of five diets. 763 ...
... -- Ronald Hoenig and Aaron Welch, both graduate ... School of Marine UM Rosenstiel School students take ... Competitionand Atmospheric Science, won first place in the ... Leigh Rothschild Entrepreneurship Competition. The two Marine ...
Cached Biology News:Nobel laureate Dr. Linda Buck elected to American Academy of Arts & Sciences 2008 Class of Fellows 2Nobel laureate Dr. Linda Buck elected to American Academy of Arts & Sciences 2008 Class of Fellows 3How to stop regaining weight? That's the real question 2Aquaculture concept leaves judges 'goggle eyed' 2
D4-GDI rabbit polyclonal antibody...
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Biology Products: